closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA DELIVERS RAPID AND SUSTAINED RELIEF FROM PRURITUS1*

Sustained reductions in pruritus up to 32 weeks1,a

aESTEEM 1 study. Data as observed from patients in the full analysis set. Results were consistent between ESTEEM 1 and ESTEEM 2.

  • Among patients treated with OTEZLA 30 mg BID, improvements in pruritus VAS scores correlated with DLQI scores (rs = 0.55 [week 16]; rs ≥0.51 [week 32]; P < 0.001)1

OTEZLA significantly reduces pruritus severity as early as week 21

*Pruritus was measured on a 100-mm VAS. Baseline values: Placebo, 65.0 mm; OTEZLA 30 mg BID, 66.1 mm.

BID, twice daily; BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.

Reference:

  1. Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514-520.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil